# Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo

> **NCT01595867** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 33 (actual)

## Conditions studied

- Narcotic Abuse
- Opioid-related Disorders
- Analgesia
- Chronic Pain

## Interventions

- **DRUG:** Placebo
- **DRUG:** EMBEDA - morphine sulfate/ naltrexone hydrochloride
- **DRUG:** morphine sulfate CR crushed.

## Key facts

- **NCT ID:** NCT01595867
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2012-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01595867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01595867, "Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01595867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*